Literature DB >> 1851995

Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells.

B Szende1, G Srkalovic, J Timar, J J Mulchahey, J D Neill, K Lapis, A Csikos, K Szepeshazi, A V Schally.   

Abstract

Previous work showed that hamster and human pancreatic tumors but not normal pancreata exhibit low-affinity cell-membrane receptors for luteinizing hormone-releasing hormone (LHRH). Although the regression of experimental pancreatic cancers induced by treatment with LHRH agonists or antagonists could be explained in part by the creation of sex-steroid deficiency, direct effects mediated by LHRH receptors might also play a role. Here, we demonstrate that pancreatic tumor cells do exhibit high-affinity binding sites for LHRH, but only in their nuclei; low-affinity sites are associated with the cell membranes. These binding sites appear to be LHRH receptors since electron microscopic immunohistochemical studies show that an antibody to the LHRH receptor reacted with sites in the nucleus of pancreatic tumor cells. Immunoreactive sites in the nucleus also were found in a restricted set of normal hamster pituitary cells thought to be luteinizing hormone-secreting cells and in MXT mouse mammary tumor cells. Such nuclear receptors may be involved in the transmission of the direct action of LHRH analogues on the tumor cells, resulting in the enhancement of programmed cell death.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851995      PMCID: PMC51616          DOI: 10.1073/pnas.88.10.4153

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid.

Authors:  K BURTON
Journal:  Biochem J       Date:  1956-02       Impact factor: 3.857

2.  Membrane receptors for peptides in experimental and human pancreatic cancers.

Authors:  M Fekete; A Zalatnai; A M Comaru-Schally; A V Schally
Journal:  Pancreas       Date:  1989       Impact factor: 3.327

3.  Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.

Authors:  M Fekete; T W Redding; A M Comaru-Schally; J E Pontes; R W Connelly; G Srkalovic; A V Schally
Journal:  Prostate       Date:  1989       Impact factor: 4.104

4.  Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  B Szende; G Srkalovic; K Groot; K Lapis; A V Schally
Journal:  J Natl Cancer Inst       Date:  1990-03-21       Impact factor: 13.506

5.  Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.

Authors:  M Fekete; A Zalatnai; A V Schally
Journal:  Cancer Lett       Date:  1989-05       Impact factor: 8.679

6.  Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.

Authors:  M Fekete; J L Wittliff; A V Schally
Journal:  J Clin Lab Anal       Date:  1989       Impact factor: 2.352

7.  Subcellular localization of the receptor for gonadotropin-releasing hormone in pituitary and ovarian tissue.

Authors:  J Marian; P M Conn
Journal:  Endocrinology       Date:  1983-01       Impact factor: 4.736

8.  Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Luteinizing hormone-releasing hormone (LH-RH) binding to purified rat pituitary nuclei.

Authors:  R P Millar; H Rosen; M Badminton; C Pasqualini; B Kerdelhue
Journal:  FEBS Lett       Date:  1983-03-21       Impact factor: 4.124

10.  Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.

Authors:  B Szende; G Srkalovic; A V Schally; K Lapis; K Groot
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

View more
  8 in total

1.  Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.

Authors:  Gabor Halmos; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC), and arachidonic acid.

Authors:  Z Naor; S Shacham; D Harris; R Seger; N Reiss
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

3.  A specifically radiolabeled somatostatin analog with strong antitumor activity induces apoptosis and accumulates in the cytosol and the nucleus of HT29 human colon carcinoma cells.

Authors:  Z Szegedi; J Takács; B Szende; Z Vadász; A Horváth; E Gulyás; G Tóth; I Peták; J Bocsi; G Kéri
Journal:  Endocrine       Date:  1999-02       Impact factor: 3.633

Review 4.  Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.

Authors:  B Fazeny; M Baur; M Prohaska; M Hudec; M Kremnitzer; S Meryn; H Huber; T Grunt; A Tuchmann; C Dittrich
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 5.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

6.  Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.

Authors:  Mark Seungwook Kim; Shaolin Ma; Anca Chelariu-Raicu; Carola Leuschner; Hector W Alila; Sanghoon Lee; Robert L Coleman; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2020-09-17       Impact factor: 6.009

7.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Authors:  Kelly K Curtis; John Sarantopoulos; Donald W Northfelt; Glen J Weiss; Kerry M Barnhart; John K Whisnant; Carola Leuschner; Hector Alila; Mitesh J Borad; Ramesh K Ramanathan
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-08       Impact factor: 3.333

8.  Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.

Authors:  P A Philip; J Carmichael; K Tonkin; P K Buamah; J Britton; M Dowsett; A L Harris
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.